{"url_path":"/sec/lnai/8-k/2026-05-13/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1527728/0001731122-26-000718-index.html","accession_number":"0001731122-26-000718","cik":"0001527728","ticker":"LNAI","issuer_name":"Lunai Bioworks Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1527728/0001731122-26-000718-index.html","primary_entity_key":"0001527728","primary_entity_name":"Lunai Bioworks Inc."},"word_count":319,"has_tables":true,"body_markdown":"**Item 5.07 Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn May 8, 2026, the Company held a special meeting\nof stockholders. The final voting results for the proposals submitted to a vote of stockholders are set forth below.\n\n \n\n**Proposal 1:**To approve an amendment to the\nCompany’s Certificate of Incorporation, as amended, to effect a reverse stock split of the outstanding shares of the Company’s\ncommon stock at a ratio in the range of 1-for-3 to 1-for-30, with the exact ratio to be determined by the Company’s Board of Directors\nin its sole discretion.\n\n \n\n**Votes For**\n**Votes Against**\n**Abstentions**\n**Broker Non-Votes**\n**Result**\n\n13,571,288\n1,153,415\n61,177\n0\nApproved\n\n \n\n**Proposal 2:**To approve the adjournment of the\nSpecial Meeting, if necessary or appropriate, including to solicit additional proxies if there are insufficient votes at the time of the\nSpecial Meeting to approve Proposal 1.\n\n \n\n**Votes For**\n**Votes Against**\n**Abstentions**\n**Broker Non-Votes**\n**Result**\n\n13,626,029\n1,091,528\n68,323\n0\nApproved\n\n \n\n**Forward-Looking Statements**\n\n \n\nThis Current Report on Form 8-K contains forward-looking\nstatements regarding the Company’s ability to regain or maintain compliance with applicable Nasdaq continued listing requirements,\nthe implementation and effects of the reverse stock split, and the continued listing of the Company’s common stock on The Nasdaq\nCapital Market. These statements are subject to risks and uncertainties, including the risk that the reverse stock split does not result\nin compliance with the Bid Price Rule, the consequences of the Mandatory Panel Monitor described above, and the other risks described\nin the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking\nstatement, except as required by law.\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange\nAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n**LUNAI BIOWORKS, INC.**\n \n\n \n \n\nDate: May 13, 2026\n \n\n \n \n\nBy:\n*/s/ David Weinstein*\n \n\nName:\nDavid Weinstein\n \n\nTitle:\nChief Executive Officer"}